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Objectives: Among infectious diseases, tuberculosis is the second leading cause 
of mortality worldwide. Since 2000, Brazil is one of twenty two countries classified 
as “high burden countries” by World Health Organization. This study aims to report 
epidemiological and economic profile of tuberculosis related hospitalizations in 
Brazil. MethOds: Retrospective analysis of Brazilian public hospital admissions for 
tuberculosis was developed according to ICD-10 classification (A15-A19) as reported 
in Brazilian Hospital Information System (SIH/SUS) database, from January 2008 to 
December 2011. Epidemiological data were extracted from public reporting system. 
Costs represent federal reimbursement values for hospitalizations (medical pro-
cedures, exams, drugs and fees) estimated in 2013 Brazilian Real (BRL). Results: 
Reported tuberculosis cases and prevalence rates per 100,000 inhabitants for 2008, 
2009, 2010, and 2011 were: 85,329 (45.0); 88,800 (46.4); 86,654 (44.8); and 89,759 (46.0), 
respectively. Hospitalizations in the same period were 18,216, 15,338, 16,153, and 
19,048, leading to a hospitalization rates of 21.35%, 17.27%, 18.64%, and 21.22% with 
mean length of stay varying from 15 to 17 days. Mortality rates showed stabil-
ity, varying from 2.95% to 3.49% for overall tuberculosis related deaths, and 6.19% 
to 8.14% for in-hospital mortality. About 40% of all deaths were related to hos-
pitalized patients. From 2008 to 2011, hospitalizations costs were 19,546,160BRL, 
21,791,027BRL, 23,889,130BRL and 29,410,353BRL, respectively, with an increase in 
cost per patient over the years (1,073BRL in 2008 to 1,544BRL in 2011). Total cost for 
the period represents 3.5% of all hospitalizations costs related to infectious diseases 
(ICD-10 chapter I). Geographic distribution indicated southeast region accounting 
for 45% of cases, 38% of hospital admissions, and 47% of costs. cOnclusiOns: 
Tuberculosis is a major public health issue, with great impact on patients’ health and 
growing hospitalization related costs for the Brazilian health care system. Southern 
region concentrates most cases and costs, probably due to the presence of important 
treatment and diagnoses centers.
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Objectives: Determine the use of antibiotics and prescription medication in pri-
mary care in the management of influenza, stratified by age, risk and complica-
tions. MethOds: A cross-sectional observational study was carried out using data 
derived from GPRD, (January 2001 - March 2009). Subjects included were: all those 
with general practitioner (GP) coded episodes of care for acute respiratory events 
related to infection (influenza and Influenza-like-illness). Analysis was stratified by 
age and ‘at-risk’ status recommended for influenza vaccination in the UK. Primary 
prescription information was collected for the following categories: antipyret-
ics/analgesics, antibiotics, amantadine, aminoglycosides, nasal decongestants, 
antisecretory drugs and mucosal protectants, and antihistamines. UK 2011 NHS 
reference costs were used. Results: A total of 53% of all patients had at least one 
medical prescription with 30% of patients receiving antibiotics. Proportionally more 
patients with complicated influenza had prescriptions (83%) compared to patients 
with uncomplicated influenza (50%), and most cases were unvaccinated. Across all 
age groups complicated influenza had a greater number of prescriptions compared 
to those with uncomplicated cases (3.0 vs. 2.5). 67% and 27% of complicated and 
uncomplicated influenza cases received antibiotics. Antipyretics and analgesics 
were prescribed to 7% of patients, with antisecretory drugs and mucosal protect-
ants prescribed to 6% of patients. Antibiotics, analgesics and antisecretory drugs 
(including mucosal protectants), were the three most commonly prescribed classes 
of drugs, and represent 41%, 31% and 12% of all prescriptions respectively. The 
annual cost is expected to be around £13,956,177 per annum with 40% of this cost 
attributable to antibiotics. cOnclusiOns: In-hospital and over-the-counter medi-
cation use is not collected in this database, therefore this is not a comprehensive 
assessment of the full extent of pharmaceutical management of influenza. The 
extensive use of antibiotics prescribed by GPs is of concern, especially in uncompli-
cated influenza episodes at a time of increasing resistance. Current clinical practice 
therefore needs urgent review.
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About 3500 people have suffered tick-borne encephalitis (TBE) in 2011 in Russia, 
and approximately 16% of them had focal form with a high case-fatality and dis-
ability rate. However, no research has investigated its social costs. Objectives: to 
evaluate the socio-economic burden of TBE in Russia. MethOds: We proposed a 
probability-tree model accounting for 4 clinical outcomes of the disease: full recov-
ery, progression to chronic disease, disability, and death; probabilities were taken 
from Russian clinical and epidemiological studies. Each outcome was associated 
with particular costs that included direct current and deferred medical and social 
costs. Tariffs of the Russian health care system were used to calculate all medical 
costs; indirect costs were estimated using the average monetary daily productivity 
and mean disability allowance. All future costs were discounted to the basis year 
(2011). The model estimated the one-year average socio-economic burden of the 
disease which could be aggregated into the gross burden by incorporating data 
on annual TBE incidence in previous years. Additionally we evaluated disability 
adjusted life years (DALYs) attributable to TBE using standard WHO methodol-
ogy. Results: We found that economic TBE burden in Russia in 2011 was about 
$49.5 million, 78% of which was deferred costs, caused by death and disability. We 
Objectives: Invasive meningococcal disease (IMD) is life-threatening and can result 
in severe sequelae. In France, no data has been published on the costs of severe IMD 
cases. This study aimed to estimate lifelong management costs associated with severe 
cases of IMD in France. MethOds: Two scenarios were developed: a 6-year old child 
with purpura fulminans resulting in amputation of both legs below the knee and a 
3-year old with meningitis and severe neurological sequelae. Additional scenarios 
included other typical sequelae of IMD: chronic renal insufficiency (CRI), profound 
deafness, epilepsy. Scenarios were validated by national experts of IMD. Health, dis-
ability, educational and other resources were obtained from experts and families of 
patients with similar sequelae. Unit costs (2013) were obtained from the literature, 
the National Health Insurance (NHI) and companies’ websites. Time horizon was 
based on life expectancies of patients (77 and 55-years respectively). A 4% discount 
rate decreasing to 2% after 30-years was applied. Costs are presented from NHI, pub-
lic funded organisations and patient or his/her private health insurance perspec-
tives. Results: Purpura fulminanswith amputations is associated with a lifelong 
discounted cost of € 768,874. Adding CRI doubles the amount (€ 1,480,545). Meningitis 
with severe neurological sequelae results in a lifelong discounted cost of € 1,924,475. 
Adding profound deafness and epilepsy slightly increases the total cost (€ 2,267,251). 
The first year is the most expensive in both scenarios (€ 166,890 and € 160,647 respec-
tively). The main cost drivers are respectively for each scenario prostheses and child/
adult stay in institutions. Overall, NHI covers 1/2 of total cost, public funded organi-
sations 1/3 and patient/private health insurance for the remainder. cOnclusiOns: 
This study fills a gap in the body of knowledge on IMD sequalae care and costs in 
France. The potentially high economic burden of IMD, in addition to its physical, 
psychological and social burden, reinforces the need for prevention.
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Objectives: In the 21st century, Brazil became the country with the most reported 
cases of dengue fever. This study aims to describe hospital costs for managing 
dengue in the Brazilian Public Healthcare System (BPHS). MethOds: BPHS Hospital 
Information Database (SIH/SUS) was used to collect data for the period of 2008-
2011. Individual claims coded as “Classic Dengue (CD) Treatment” or “Dengue 
Hemorrhagic Fever (DHF) Treatment” in the SIH/SUS (regardless ICD-10 codes) 
were identified in this system and compiled by geographic region, disease type and 
year. Results: A total of 304,548 individual dengue claims were obtained for the 
2008-2011 period. They represented an overall cost of 97,642,495BRL for all 4 years 
(ranging from 17,843,318BRL in 2009 to 31,235,501BRL in 2010). The 4-year national 
average cost per inpatient admission was 321BRL (295BRL [2008] - 333 BRL [2010]), 
with mean length of stay (LOS) of 3.3 days and in-hospital mortality rate of 0.46%. 
The northeast region represented 43.1% of overall expenditures, while the south 
accounted for only 1.6%. The hemorrhagic syndrome was responsible for 10%, 7% 
and 10% of overall cost, individual dengue claims and total hospitalization days, 
respectively. Mean cost per inpatient admission for DHF was 50.6% higher than CD’s 
(468BRL vs. 316 BRL), mean LOS was 55.2% higher (5.0 vs. 3.2 days) and in- hospital 
mortality rate was 997.8% higher than the one from CD (3.0% vs. 0.27%). Stratifying 
by region, 9.6%, 36.6%, 34.7%, 1.7% and 17.4% of DHF costs were respectively local-
ized on the North, Northeast, Southeast, South and Midwest. cOnclusiOns: The 
analysis of SIH/SUS administrative information provided insightful information 
about dengue costs. Although DHF represented only 7% of individual claims, its 
mean cost per inpatient admission and in-hospital mortality rate was considerably 
higher than CD’s, persisting as an object of concern for health authorities.
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Objectives: Herpes zoster (HZ) and post-herpetic neuralgia (PHN), one of its more 
severe and frequent complication, are very painful and debilitating conditions. The 
societal economic burden of HZ in Sweden is not well described today. The objec-
tive of this study is to describe the burden of HZ and PHN in Sweden in the year 
2011. MethOds: Data for inpatient care, outpatient primary care, the prescriptions 
of drugs, sick leave and the number or diagnostic tests were collected from national 
databases. The incidence of the HZ was estimated based on the number of prescrip-
tions of antiviral drugs, on which a correcting factor has been applied. Results: 
Almost 30,000 patients were diagnosed with HZ, with two third occurring in patients 
older than 50 years. The societal cost to treat these patients, including the cost to treat 
those patients who later developed PHN, added up to nearly 227 MSEK (21M€ ) which 
corresponds to 7,600 SEK per patient (876€ ). The main contributors to the total cost for 
the treatment of HZ patients were primary care (43%); sick leave (28%); hospitalization 
(10%) and specialist care (7%). Medication was a relatively small contributor with 8.5 
MSEK (4%) to the overall costs for patients at all ages. cOnclusiOns: The current 
study demonstrates that the burden of HZ is significant in Sweden, especially in 
people aged 50 years and older. This economic burden is expected to increase in the 
coming years since the population older than 50 years represents a growing propor-
tion of the population. Thus, the society and the health care payers potentially have 
a lot to gain by introducing a vaccination program to patients aged 50 years and older, 
to reduce the burden and increase their quality-of-life.
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Results based on a large and representative patient sample demonstrate that the cost 
of seasonal influenza episodes is substantial, especially when complications occur. 
Costs in children may be higher of what is actually reported.
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Objectives: Clostridium difficile is the leading cause of antibiotic associated infec-
tious nosocomial diarrhoea. C. difficile infection is a high-priority problem of public 
health in each country. The available literature of C. difficile infection’s disease bur-
den is limited. The authors aimed to identify the most important cost elements and 
quantify the cost of C. difficile infection in Hungary. MethOds: A retrospective chart 
review and experts interviews were done in a sample of 151 patients with C. difficile 
infection in 2011 in two Hungarian hospitals. In the chart review data on demographic, 
disease severity, therapy, the standard precautions and the infection related contact 
precautions were collected. Cost analysis was done from the service provider’s per-
spective. Results: In department of medicine the annual average cost of C. difficile 
infection was € 800 per patient, the annual total cost of a recurrent patient was € 1810, 
the annual additional cost of contact precautions was € 330 per patient, the annual 
average cost of an episode was € 570, the additional cost of contact precautions was 
€ 235 per episode. In intensive care unit the annual average cost of C. difficile infec-
tion was € 1810 per patient, the annual total cost of a recurrent patient was € 3680, 
the annual additional cost of contact precautions was € 470 per patient, the annual 
average cost of an episode was € 1070, the additional cost of contact precautions 
was € 330 per episode. The most notable cost elements in intensive care unit were 
the hygienic costs and nurse wages, in department of medicine were the hygenic 
costs. cOnclusiOns: The importance of C. difficile infection in public health and 
the associated disease burden are significant. The costs differed based on the length 
of isolation, and the type of the provider department. The available data in Hungary 
are limited, further studies in epidemiology and health economics are required.
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Objectives: This analysis was conducted to demonstrate potential downstream 
health care cost savings as a result of increasing vaccination rates for influenza 
in the United States. MethOds: An age-structured susceptible-exposed-infec-
tious-recovered (SEIR) compartmental model was constructed to model the course 
of influenza infection over the course of 1 year in the United States. A realistic 
age structure was incorporated using mixing rates between age groups from the 
European POLYMOD survey. The SEIR model was adapted to include another com-
partment for vaccination. A series of difference equations was used to model 
transitions to and from each compartment. Time-dependent vaccination rates 
were obtained using monthly estimates of vaccination rates obtained from the 
Centers for Disease Control and Prevention (CDC). Cost and health care utilization 
data were obtained from the existing literature, and included outpatient visits, 
hospitalization, and antiviral drug treatment. Costs were reported in 2013 U.S. 
dollars. Microsoft Excel 2011 was used to conduct the analysis. Results: Under 
a base case vaccination rate of 40 percent, an estimated 11 percent of individu-
als in the United States were projected to have symptoms of influenza infection. 
Health care costs attributable to influenza infection were estimated to be $13.6 
billion. Increasing vaccination rates to 50 percent decreased the percentage of 
symptomatic individuals to approximately 7 percent, resulting in downstream 
health care costs of $9.5 billion. Further increasing vaccination rates to 60 percent 
is projected to further reduce downstream health care costs to approximately $5.0 
billion. cOnclusiOns: This exploratory analysis demonstrates that significant 
health care cost savings can be realized by increasing vaccination rates for influ-
enza in the population.
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Objectives: Achieving optimal outcomes in the treatment of HIV requires high, 
sustained levels of medication adherence to antiretroviral therapy (ART). Across many 
conditions, suboptimal adherence has been shown to lead to poorer outcomes among 
patients. This study assessed the extent to which patients diagnosed with HIV are 
adherent with ART treatment guidelines and to illustrate associations between ART 
adherence and economic outcomes. MethOds: Commercially insured and Medicaid 
patients in the US from MarketScan claims databases with ≥ 2 claims containing an 
HIV/AIDS diagnosis code between June 1, 2006 and December 31, 2011 who received 
an ART prescription between June 1, 2007 and December 31, 2010 were selected for 
initial inclusion. For each patient, the first ART prescription received during that time 
defined the index date. Patients were ≥ 18 years old on their index date and had ≥ 12 
months of continuous health plan enrollment with drug benefits before and after 
their index date. Adherence was measured by patients’ proportion of days covered 
(PDC) with a complete ART regimen during the 12-month post-index date period; 
patients with PDC ≥ 80% were considered adherent. Multivariable models (i.e., general-
ized linear; Poisson) assessed the relationship between ART adherence and economic 
outcomes (i.e., costs; number of health care encounters), controlling for demographic 
and clinical characteristics. Results: A total of14,590 commercially insured patients 
met all inclusion criteria, and 59% were adherent; 5,744 Medicaid patients met all 
estimate total 4177 DALYs caused by TBE in 2011. cOnclusiOns: TBE burden is 
quite large in Russia, thus economic evaluation of preventive measures is essential 
in order to choose the most cost-effective options.
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Objectives: Chronic hepatitis C virus (HCV) infection is estimated to effect 
approximately 15 million persons in Europe. It is a prevalent cause of progres-
sive liver disease including cirrhosis and hepatocellular carcinoma (HCC) and 
nearly 90,000 deaths that occur annually in the European region are related to 
HCV infection. The objective of this study was to evaluate the direct health care 
costs of HCV infection in countries of the European Union. MethOds: ENTREZ 
PUBMED was searched systematically for studies published between 2008 and 2013 
that evaluated the health care costs of persons with HCV infection in countries 
of the European Union. Of the 110 studies identified only 3 contained overall 
health care costs. Cost data was extracted, inflation adjusted to 2013 costs and 
averaged. Results: Based on the included studies, the average annual health 
care cost for a person with chronic HCV infection is € 2,756 with mild disease, 
€ 6,258 with cirrhosis, and € 11,437 with HCC. An HCV-related liver transplanta-
tion is estimated to have an average cost of € 68,497. The reported annual health 
care costs of patients with chronic HCV infection vary widely, with annual costs 
ranging between € 340 and € 6,773 among those categorized as having chronic 
infection and/or mild disease and between € 34,834 and € 124,594 among those who 
have had a liver transplantation. cOnclusiOns: The majority of recent studies 
have investigated antiviral drug treatment costs; few have examined the overall 
health care costs associated with chronic HCV infection in Europe. Based upon the 
data available, chronic HCV infection is associated with a substantial health care 
burden even among those categorized as having mild disease. Further research is 
needed to better understand the costs of HCV infection to enable more relevant 
screening and treatment strategies, especially among those at high risk for devel-
oping severe liver disease.
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Objectives: Bordetella pertussisinfection is highly contagious and can progress 
to severe conditions, especially among young children and elderly. This study aims 
to describe hospitalization patterns and costs for pertussis in children in public 
hospitals in Brazil, from 2008 to 2011. MethOds: A retrospective analysis of Brazil 
public hospital admissions for pertussis was developed according to ICD-10 classi-
fication (A37: Pertussis) in children (aged ≤ 9 years), as reported in Brazilian Hospital 
Information System (SIH/DATASUS) database from January 2008 to December 2011. 
Costs represents federal reimbursement values for hospitalizations (includes medi-
cal procedures, exams, medications and taxes), presented in 2013 Brazilian Real 
(BRL). Results: A total of 3055 hospital admissions for pertussis during the four-
year period were identified. There was a downward trend in the first three years 
of the analysis, while the opposite occurred in the fourth year, with 2011 having 
the highest number of cases (907, 655, 394 and 1,099 for 2008, 2009, 2010, and 2011, 
respectively). Infants were the most affected, with those less than one year of age 
accounting for 91% (n = 2,779) of all pertussis admissions in the age group analyzed. 
In-hospital mortality rate was 13.9% for all cause in the period. Mean length of stay 
was 7.56 days. Total cost for the period was 3,754,877 BRL, which represents 94.9% 
of pertussis hospitalization costs for all ages (3,958,133 BRL). Mean cost per patient 
was 1,229 BRL. cOnclusiOns: The costs with pertussis hospitalizations in children 
can be substantial in Brazil, from the public health care perspective. Despite the 
existence of a National Immunization Program, the number of cases in children 
remains high. It is therefore important that decision makers reassess the prevention 
and treatment patterns of this disease.
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Objectives: To evaluate cost of children and adults diagnosed with seasonal 
influenza in Germany, filling a data gap of more than a decade. MethOds: This 
cost-of-illness study was conducted from payer and societal perspective based on 
a retrospective database analysis by using a longitudinal electronic medical records 
database (IMS® Disease Analyzer). Patients with influenza episodes (ICD-10 diagnosis 
J09-11) being observable 12 months before index date and 1 month afterwards were 
included. The selection window was May 2010 to April 2012 to cover two influenza sea-
sons. Published unit costs and tariffs for Germany in 2012 were used. Results: A total 
of 23,068 influenza episodes (19,446 patients) managed by primary care practitioners 
(PCP) and 7,295 episodes (5,988 patients) managed by pediatricians were eligible for 
analysis. Mean age of patients with at least one episode was 43 years (SD 20) in the PCP 
panel and 7 years (SD 4) in the pediatrician panel. Total average mean cost (SD) from 
societal perspective in adult patients was € 471 (576) and in children € 99 (140)/episode. 
In about 11% of the adult patients the total cost exceeds € 1,000/episode. This is primar-
ily due to the higher percentage of patients with complications (63%) compared to the 
entire PCP study cohort (38%). Workdays lost were the main cost driver (82%) in adult 
patients; more than 40% of patients missed between 2 and 6 days of work/episode. 
In children, the main cost driver was physician visits (66%). Complications increase 
the cost by three fold in children and two fold in adults (average mean cost (SD) for 
children: € 137 (144) vs. € 49 (33) and adults: € 622 (670) vs. € 377 (485)). cOnclusiOns: 
